Literature review
3infection targets assessed
Focus the science
We examined rhinovirus prophylaxis and therapeutic approaches for P. gingivalis and acne.
Case Study · Scientific Assessment
Antibodies as a backup for vaccine programs.
A global pharmaceutical company wanted to know if monoclonal antibodies could complement or de-risk its vaccine development, especially in high-risk populations. Prescouter reviewed the science, clinical evidence and global regulations, and assessed three infection targets.
The Client
The client is a global pharmaceutical company developing vaccines. It wanted to know if monoclonal antibodies could become part of its vaccine de-risking strategy.
The Challenge
Long vaccine timelines.
An immediate backup?
Monoclonal antibodies provide immediate passive immunity and suit narrow, high-risk populations. The client needed to weigh their scientific, clinical, regulatory and economic potential against conventional vaccines.
-
Clinical
Efficacy in high-risk groups
Evidence for preventing infection.
-
Regulatory
Approval precedents
Pathways, timelines and hurdles.
-
Economic
Manufacturing demand
Cost of goods at projected volumes.
Our Approach
Science, clinic and regulation, target by target.
Clinical evidence
Durationof immunity examined
Weigh the trade-offs
We reviewed how long protection lasts and challenges such as anti-drug antibody induction.
Regulatory review
Globalregulatory guidelines analyzed
Chart the pathway
US, European and other guidelines revealed precedents, timelines and hurdles versus vaccines.
The Outcome
Clear targets, realistic doses.
For rhinovirus, Prescouter found that doses of 1.8 to 3.6 g per patient are plausible for a multi-mAb cocktail, with cost-of-goods modeling confirming the need for strategic production investment. For acne, IL-17A/F and CAMP factors emerged as promising targets, with nanobodies and nanoparticle delivery offering localized options. For P. gingivalis, gingipains, fimbriae and OmpA-like proteins led the target list, with sustained-release systems as potential enablers.
-
Rhinovirus
Multi-mAb cocktail
Plausible doses for intramuscular use.
-
Acne
Localized delivery
Nanobodies and nanoparticle systems.
-
Oral health
Sustained release
Lipid nanoparticles and depot systems.
A backup strategy is only useful if it is ready when the primary plan stalls. Knowing the targets, doses and regulatory precedents in advance turns a fallback into a real option.
Let’s Talk
How resilient is your development pipeline?
Assess the scientific, clinical, regulatory and economic case for alternative approaches in your pipeline. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]